Singapore markets close in 3 hours 19 minutes

iX Biopharma Ltd. (42C.SI)

SES - SES Delayed Price. Currency in SGD
Add to watchlist
0.24000.0000 (0.00%)
As of 1:15PM SGT. Market open.

iX Biopharma Ltd.

No. 14-01 Great World City East Tower
1 Kim Seng Promenade
Singapore 237994
Singapore
65 6235 2270
http://www.ixbiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees

Key executives

NameTitlePayExercisedYear born
Prof. Chin Beng LimChief PharmacistN/AN/AN/A
Mr. Yip Hang LeeChairman & CEON/AN/A1954
Mr. Sien Lup ChewChief Financial OfficerN/AN/A1963
Dr. Janakan KrishnarajahCOO & Chief Medical OfficerN/AN/AN/A
Dr. Iain Bruce CookChief ScientistN/AN/A1960
Ms. Eva TanChief Commercial OfficerN/AN/AN/A
Mr. Wei Hsiung Lee A.C.I.S., ACISJoint Company Sec.N/AN/AN/A
Mr. Shin Lin Wang A.C.I.S., ACISJoint Company Sec.N/AN/AN/A
Mr. Chia Hsing YeeDirector of Corp. Affairs & GM of Entity HealthN/AN/A1972
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SGD.

Description

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in China, Australia, and Singapore. The company operates through Specialty Pharmaceutical and Nutraceutical segments. Its lead product candidate is Wafermine, a sublingual ketamine oral wafer for the treatment of acute moderate to severe pain, as well as for major depressive disorder. The company also offers Xativa, a sublingual cannabidiol wafer for the treatment of anxiety, relieving pain, reducing inflammation, and improving sleep quality; BnoX, a sublingual buprenorphine wafer for the management of acute and chronic moderate to severe pain; and Wafesil and Silcap for the treatment of male erectile dysfunction. In addition, it offers LumeniX for skin lightening and immunity; WafeRest for the promotion of sleep; and SL-NAD+ product. Further, the company promotes and markets nutritional and supplements products through pharmacies and health food shops, as well as through online; develops and commercializes of nutraceutical products; provides laboratory services; JD and Tmall e-commerce platforms in China; and markets and distributes products in Europe. iX Biopharma Ltd. was founded in 2008 and is headquartered in Singapore.

Corporate governance

iX Biopharma Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.